Read this manager's filing book
Disclosed positions
KOTLER KEVIN: source evidence dated 2026-02-18T04:59:59.999Z.
- Issuer
- SPDR S&P 500 ETF TR
- Ticker
- SPY
- Class
- TR UNIT
- Reported value
- $238,672,000
- Reported amount
- 350,000
- Unit
- SH
- Option
- Put
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0000919574-26-001069Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| SPDR S&P 500 ETF TR | SPY | TR UNIT | $238,672,000 | 350,000 | SH | Put |
| INVESCO QQQ TR | QQQ | UNIT SER 1 | $30,715,500 | 50,000 | SH | Put |
| ANGIODYNAMICS INC | ANGO | COM | $21,997,218 | 1,713,789 | SH | None |
| AURINIA PHARMACEUTICALS INC | AUPH | COM | $19,536,294 | 1,224,846 | SH | None |
| AVADEL PHARMACEUTICALS PLC | AVDL | COM SHS | $18,951,070 | 879,400 | SH | Call |
| AVADEL PHARMACEUTICALS PLC | AVDL | COM SHS | $15,975,942 | 741,343 | SH | None |
| OMEROS CORP | OMER | COM | $15,554,281 | 905,635 | SH | None |
| NEUROPACE INC | NPCE | COM | $9,749,866 | 631,468 | SH | None |
| MEDIWOUND LTD | MDWD | SHS NEW | $6,225,377 | 337,236 | SH | None |
| AXOGEN INC | AXGN | COM | $5,498,640 | 168,000 | SH | None |
| INTEGRA LIFESCIENCES HLDGS C | IART | COM NEW | $5,308,867 | 427,445 | SH | None |
| ACLARIS THERAPEUTICS INC | ACRS | COM | $5,134,846 | 1,705,929 | SH | None |
| VERTICAL AEROSPACE LTD | Unresolved | SHS NEW | $5,008,628 | 939,705 | SH | None |
| ORASURE TECHNOLOGIES INC | OSUR | COM | $4,359,499 | 1,801,446 | SH | None |
| OMEROS CORP | OMER | COM | $3,794,445 | 218,700 | SH | Call |
| GALAPAGOS NV | GLPG | SPON ADR | $2,943,000 | 90,000 | SH | None |
| ELI LILLY & CO | LLY | COM | $2,149,360 | 2,000 | SH | None |
| CERUS CORP | CERS | COM | $2,083,925 | 1,011,614 | SH | None |
| NIKE INC | NKE | CL B | $2,038,720 | 32,000 | SH | None |
| TECTONIC THERAPEUTIC INC | TECX | COM | $1,668,800 | 80,000 | SH | None |
| CLIMB BIO INC | CLYM | COM | $1,600,000 | 400,000 | SH | None |
| TREACE MED CONCEPTS INC | TMCI | COM | $1,162,194 | 474,365 | SH | None |
| TRISALUS LIFE SCIENCES INC | TLSI | COM | $1,013,496 | 145,200 | SH | None |
| DEXCOM INC | DXCM | COM | $995,550 | 15,000 | SH | None |
| VANDA PHARMACEUTICALS INC | VNDA | COM | $882,000 | 100,000 | SH | None |
| ALIGN TECHNOLOGY INC | ALGN | COM | $680,658 | 4,359 | SH | None |
| ONKURE THERAPEUTICS INC | OKUR | COM CL A | $573,304 | 197,691 | SH | None |
| GE AEROSPACE | GE | COM NEW | $452,188 | 1,468 | SH | None |
| PULMONX CORP | LUNG | COM | $442,000 | 200,000 | SH | None |
| PTC THERAPEUTICS INC | PTCT | COM | $379,800 | 5,000 | SH | None |
| DYCOM INDS INC | DY | COM | $355,133 | 1,051 | SH | None |
| TAKEDA PHARMACEUTICAL CO LTD | TAK | SPONSORED ADS | $311,800 | 20,000 | SH | None |
| BETA BIONICS INC | BBNX | COM | $250,342 | 8,216 | SH | None |
| ISHARES TR | IHI | U.S. MED DVC ETF | $242,509 | 3,902 | SH | None |
| BANK AMERICA CORP | BAC | COM | $241,560 | 4,392 | SH | None |
| AMAZON COM INC | AMZN | COM | $230,820 | 1,000 | SH | None |
| ELANCO ANIMAL HEALTH INC | ELAN | COM | $205,299 | 9,072 | SH | None |
| PLIANT THERAPEUTICS INC | PLRX | COM | $113,460 | 93,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 4 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.